Clinical Trials
Eli Lilly Reports Detailed Data from the P-III (SURMOUNT-OSA) Trial of Tirzepatide to Treat Obstructive Sleep Apnea
Read More: Eli Lilly Date: June 24, 2024
AstraZeneca Reports Updated Data from the P-III (ADJUVANT BR.31) Study of Imfinzi to Treat Non-Small Cell Lung Cancer
Read More: AstraZeneca Date: June 25, 2024
Sanofi Reports the P-II Study Data of Riliprubart to Treat Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Read More: Sanofi Date: June 26, 2024
Neurobo Pharmaceuticals Reports First Patient Dosing in P-I Study of DA-1726 to Treat Obesity
Read More: Neurobo Pharmaceuticals Date: June 27, 2024
Regulatory
Takeda’s Fruzaqla Gains the EC’s Approval for the treatment of Metastatic Colorectal Cancer
Read More: Takeda Date: June 24, 2024
BMS’ Krazati Receives the US FDA’s Accelerated Approval to Treat Locally Advanced or Metastatic Colorectal Cancer (mCRC)
Read More: BMS Date: June 24, 2024
argenx’ Vyvgart Hytrulo Bags the US FDA’s Approval for Treating Chronic Inflammatory Demyelinating Polyneuropathy
Read More: argenx Date: June 24, 2024
GSK Reports the Japanese MHLW’s Approval of Omjjara (momelotinib) for Treating Myelofibrosis
Read More: GSK Date: June 25, 2024
Daiichi Sankyo Reports the MHLW’s Approval of Ezharmia (Valemetostat Tosilate) To Treat Peripheral T-Cell Lymphoma
Read More: Daiichi Sankyo Date: June 25, 2024
Roche’s Ocrevus SC (Ocrelizumab) Receives the EC’s Approval to Treat Multiple Sclerosis
Read More: Roche Date: June 25, 2024
AstraZeneca’s Tagrisso Plus Chemotherapy Receives Japanese Approval to Treat EGFR-Mutated Advanced Lung Cancer
Read More: AstraZeneca Date: June 26, 2024
AbbVie Receives Complete Response Letter for ABBV-951’s NDA to Treat Parkinson’s Disease
Read More: AbbVie Date: June 26, 2024
AstraZeneca’s Tagrisso Plus Chemotherapy Receives NMPA’s Approval to Treat EGFR-Mutated Advanced Lung Cancer
Read More: AstraZeneca Date: June 27, 2024
AbbVie’s Epkinly (epcoritamab-bysp) Receives the US FDA’s Accelerated Approval to Treat R/R Follicular Lymphoma
Read More: AbbVie Date: June 27, 2024
M&A
Altaris Reports the Acquisition of Sharecare
Read More: Altaris & Sharecare Date: June 24, 2024
Quest Diagnostics Reports the Acquisition of Lab Assets from Allina Health
Read More: Quest Diagnostics & Allina Health Date: June 27, 2024
AbbVie Reports the Acquisition of Celsius Therapeutics
Read More: AbbVie & Celsius Therapeutics Date: June 28, 2024
Med Tech
The US FDA Grants Clearance to Alcon’s Unity VCS and Unity CS for Eye Care
Read More: Alcon Date: June 24, 2024
Evolus Reports Premarket Approval Application Submission to the US FDA for Evolysse Dermal Filler Products
Read More: Evolus Date: June 25, 2024
Tempus Reports the US FDA’s Approval of Tempus ECG-AF to Detect Patients at Risk of Atrial Fibrillation
Read More: Tempus Date: June 27, 2024
Pharma
Rani Therapeutics Collaborates with ProGen to Develop RT-114 for Obesity
Read More: Rani Therapeutics & ProGen Date: June 25, 2024
Animal Health
Merck Animal Health’s Nobivac NXT Canine Flu H3N2 Receives the USDA’s Approval for Canine Influenza
Read More: Merck Animal Health Date: June 26, 2024
PetPace Brings Out AI-Based Pregnancy Monitoring Module to Improve Pet Health at EVSSAR 2024
Read More: PetPace Date: June 28, 2024
COVID- 19
The EC Approves Biogen’s Tofidence (Biosimilar, Roactemra) for Treating Arthritis and COVID-19
Read More: Merck Animal Health Date: June 26, 2024
Pfizer and BioNTech Report the CHMP’s Positive Opinion of Comirnaty JN.1 Vaccine for COVID-19
Read More: Pfizer & BioNTech Date: June 28, 2024
Digital Health
InfoBionic.Ai Collaborates with Anumana to Advance AI-Based Technology for Early Detection of Cardiac Diseases
Read More: InfoBionic.Ai & Anumana Date: June 26, 2024
Biosimilar
The NMPA Approves Simcere Zaiming’s Enlituo (Biosimilar, Cetuximab Beta) as a 1L Treatment for Metastatic Colorectal Cancer (mCRC)
Read More: Simcere Zaiming Date: June 27, 2024
Coherus Reports the Divestment of Yusimry (Biosimilar, Humira) to Hong Kong King-Friend Industry
Read More: Coherus Date: June 28, 2024
